nited Kingdom Trial for children and young adults with Acute lymphoblastic Leukaemia and Lymphoma 2011

Phase 3

• Conditions: Paediatric Oncology; Disease: Lymphoma (Hodgkin's), Leukaemia (acute lymphoblastic); Cancer; Hodgkin lymphoma

• Registration Number: ISRCTN64515327
• Lead Sponsor: niversity of Birmingham (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-12-08
• Last Update Posted: 15 May 2023
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 2822

Inclusion Criteria

1. Aged 1 (first birthday) to 24 years 364 days (at time of diagnosis)
2. First diagnosis of acute lymphoblastic leukaemia or lymphoblastic lymphoma (T-NHL or SmIG negative precursor B-NHL) diagnoses using standard criteria
3. Male and female participants

Exclusion Criteria

1. Infants less than a year old at diagnosis
2. Patients diagnosed with B-ALL (Burkitt-like, t(8;14), L3 morphology, SMIg positive)
3. Patients diagnosed with Philadelphia-positive ALL (t(9;22) or BCR/ABL positive)
4. Patients in whom written informed consent has not been obtained from parents and/or patients prior to randomisation
5. Patients who have received previous treatment for ALL or lymphoblastic lymphoma (LBL) except those patients who have received dexamethasone treatment for no more than 7 days (due to clinical urgency) immediately prior to randomisation

Study & Design

• Study Type: Interventional
• Study Design: Not specified